Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | BCMA-specific CAR-T cells for R/R multiple myeloma

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, evaluates the efficacy and safety of B-cell maturation antigen-specific (BCMA) CAR-T cells for relapsed/refractory multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.